HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

VU 0405652

structure in first source

Also Known As:

ML 169; ML-169; ML169 cpd; VU-0405652; VU0405652

Networked: 2 relevant articles (0 outcomes, 1 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - VU 0405652: 2
Organic Chemicals: 133
- Sulfur Compounds: 278
  - Sulfones: 534
    - VU 0405652: 2

Experts

1.	Ali, Khadra Mohamed: 1 article (04/2021)
2.	El Gammal, Eid Rizk: 1 article (04/2021)
3.	Eladl, Hadaya Mosaad: 1 article (04/2021)
4.	Deuren, Marcel van: 1 article (12/2005)
5.	Eijk, Lucas van: 1 article (12/2005)
6.	Hoeven, Hans van der: 1 article (12/2005)
7.	Pickkers, Peter: 1 article (12/2005)
8.	Smits, Paul: 1 article (12/2005)
9.	Sprong, Tom: 1 article (12/2005)

Related Diseases

1.	Pain (Aches) 04/01/2021 - "The mean±standard deviation for limb volume, shoulder flexion, abduction, and pain score were 2,108.71±200.97 mL, 169.68°±4.54°, 150.44°±3.92°, and 3.16±1.1 in the study group and 2,256.41±186.94 mL, 147.36°±5.32°, 131.32°±4.38°, and 5.68±0.94 in the control group, respectively. "
2.	Shock 12/01/2005 - "VEGF plasma concentrations were increased (median 193 pg/mL, range 71-1082) and were highest in the presence of shock (208 pg/mL, 169-1082) compared with patients presenting without shock (92 pg/mL range 71-299). "

Related Drugs and Biologics

1.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)